Zhejiang Starry Pharmaceutical Co.,Ltd.
Shanghai Stock Exchange 603520.SS
Zhejiang Starry Pharmaceutical Co.,Ltd. Free Cash Flow for the year ending December 31, 2023: USD -31.22 M
-
Zhejiang Starry Pharmaceutical Co.,Ltd. Free Cash Flow for the year ending December 31, 2022 was USD -79.78 M, a -347.33% change year over year.
-
Zhejiang Starry Pharmaceutical Co.,Ltd. Free Cash Flow for the year ending December 31, 2021 was USD 32.26 M, a 887.92% change year over year.
-
Zhejiang Starry Pharmaceutical Co.,Ltd. Free Cash Flow for the year ending December 31, 2020 was USD 3.27 M, a -79.97% change year over year.
-
Zhejiang Starry Pharmaceutical Co.,Ltd. Free Cash Flow for the year ending December 31, 2019 was USD 16.30 M, a 280.83% change year over year.
| Date | Free Cash Flow | Operating Cash Flow | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities |
|---|
| CEO | Mr. Weiyi Shen |
| IPO Date | March 9, 2016 |
| Location | China |
| Headquarters | Xianju modern industrial cluster |
| Employees | 1,845 |
| Sector | Health Care |
| Industries | |
Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products comprise levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is based in Xianju, China.
Past 5 years
USD 3.33
USD 1.67
USD 2.19
USD 1.78
USD 2.17
StockViz Staff
January 15, 2025
Any question? Send us an email